Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 24, 2016, Pages E3384-E3393

  Kodama, Takahiro ^a   Newberg, Justin Y ^a   Kodama, Michiko ^a   Rangel, Roberto ^a   Yoshihara, Kosuke ^b   Tien, Jean C ^c   Parsons, Pamela H ^d   Wu, Hao ^d   Finegold, Milton J ^d   Copeland, Neal G ^a   Jenkins, Nancy A ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

EMT; HCC; Met; Transposon; Ubiquitin mediated proteolysis

Indexed keywords

NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 12; SCATTER FACTOR RECEPTOR; SORAFENIB; UBIQUITIN; TRANSPOSON; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GAB1 GENE; GENE IDENTIFICATION; GENE SEQUENCE; HECT GENE; HUMAN; HUMAN CELL; HUWE1 GENE; KDM6A GENE; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SLEEPING BEAUTY TRANSPOSON; TRANSPOSON; TUMOR GENE; UBA GENE; UPREGULATION; ANIMAL; CELL MOTION; GENETICS; LIVER TUMOR; METABOLISM; NUDE MOUSE; TRANSGENIC MOUSE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; DNA TRANSPOSABLE ELEMENTS; EPITHELIAL-MESENCHYMAL TRANSITION; LIVER NEOPLASMS; MICE; MICE, NUDE; MICE, TRANSGENIC; MUTAGENESIS; NEOPLASM PROTEINS;

EID: 84974667989     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1606876113     Document Type: Article

References (63)

1. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822): 1245-1255.
2. Mittal S, El-Serag HB (2013) Epidemiology of hepatocellular carcinoma: Consider the population. J Clin Gastroenterol 47(Suppl):S2-S6.
3. National Comprehensive Cancer Network (2016) NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers (National Comprehensive Cancer Network, Fort Washington, PA).
4. Llovet JM, et al.; SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390.
5. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178-196.
6. De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13(2):97-110.
7. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420-1428.
8. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871-890.
9. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J (2012) Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22(6):725-736.
10. Mani V, et al. (2008) Serial in vivo positive contrast MRI of iron oxide-labeled embryonic stem cell-derived cardiac precursor cells in a mouse model of myocardial infarction. Magn Reson Med 60(1):73-81.
11. Sampieri K, Fodde R (2012) Cancer stem cells and metastasis. Semin Cancer Biol 22(3): 187-193.
12. Fischer KR, et al. (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527(7579):472-476.
13. Zheng X, et al. (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527(7579):525-530.
14. Yang MH, et al. (2009) Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 50(5): 1464-1474.
15. Jou J, Diehl AM (2010) Epithelial-mesenchymal transitions and hepatocarcinogenesis. J Clin Invest 120(4):1031-1034.
16. Xia L, et al. (2013) Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 57(2):610-624.
17. Ding W, et al. (2010) Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 52(3):945-953.
18. Zhai B, Sun XY (2013) Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 5(7):345-352.
19. Chow AK, et al. (2013) The enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One 8(11):e78675.
20. Chen X, et al. (2011) Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol 55(4):838-845.
21. Nagai T, et al. (2011) Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 10(1): 169-177.
22. Bard-Chapeau EA, et al. (2014) Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet 46(1):24-32.
23. Mann MB, et al. (2015) Transposon mutagenesis identifies genetic drivers of Braf (V600E) melanoma. Nat Genet 47(5):486-495.
24. Takeda H, et al. (2015) Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nat Genet 47(2):142-150.
25. Koso H, et al. (2012) Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. Proc Natl Acad Sci USA 109(44):E2998-E3007.
26. Strick-Marchand H, Weiss MC (2002) Inducible differentiation and morphogenesis of bipotential liver cell lines from wild-type mouse embryos. Hepatology 36(4 Pt 1): 794-804.
27. Zhang W, et al. (2012) Efficient generation of functional hepatocyte-like cells from human fetal hepatic progenitor cells in vitro. J Cell Physiol 227(5):2051-2058.
28. van Zijl F, et al. (2009) Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 5(8):1169-1179.
29. March HN, et al. (2011) Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 43(12):1202-1209.
30. Brett BT, et al. (2011) Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors. PLoS One 6(9): e24668.
31. Futreal PA, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4(3): 177-183.
32. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 12(2):89-103.
33. Ngan E, Northey JJ, Brown CM, Ursini-Siegel J, Siegel PM (2013) A complex containing LPP and α-actinin mediates TGFβ-induced migration and invasion of ErbB2-expressing breast cancer cells. J Cell Sci 126(Pt 9):1981-1991.
34. Risolino M, et al. (2014) Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-β-SMAD3 pathway in non-small cell lung adenocarcinoma. Proc Natl Acad Sci USA 111(36):E3775-E3784.
35. Arima Y, et al. (2010) Decreased expression of neurofibromin contributes to epithelial- mesenchymal transition in neurofibromatosis type 1. Exp Dermatol 19(8): e136-e141.
36. Choi HJ, et al. (2015) UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1. EMBO Rep 16(10): 1288-1298.
37. van den Beucken T, et al. (2014) Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun 5:5203-5215.
38. Chandramouli A, Simundza J, Pinderhughes A, Cowin P (2011) Choreographing metastasis to the tune of LTBP. J Mammary Gland Biol Neoplasia 16(2):67-80.
39. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2(2):329-333.
40. Mazzone M, Comoglio PM (2006) The Met pathway: Master switch and drug target in cancer progression. FASEB J 20(10):1611-1621.
41. Cecchi F, Rabe DC, Bottaro DP (2012) Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 16(6):553-572.
42. Giordano S, Columbano A (2014) Met as a therapeutic target in HCC: Facts and hopes. J Hepatol 60(2):442-452.
43. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E (1997) Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 25(4):862-866.
44. Qi XS, Guo XZ, Han GH, Li HY, Chen J (2015) MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol 21(18):5445-5453.
45. Inoue S, et al. (2013) Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes Dev 27(10): 1101-1114.
46. Gruber S, et al. (2013) Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6Rα signaling. Cell Reports 4(4):669-680.
47. Yumimoto K, et al. (2015) F-box protein FBXW7 inhibits cancer metastasis in a non- cell-autonomous manner. J Clin Invest 125(2):621-635.
48. Yu J, et al. (2014) FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition. Hepatobiliary Pancreat Dis Int 13(2):184-191.
49. Sun T, et al. (2011) Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 144(5):703-718.
50. Rhee I, Zhong MC, Reizis B, Cheong C, Veillette A (2014) Control of dendritic cell migration, T cell-dependent immunity, and autoimmunity by protein tyrosine phosphatase PTPN12 expressed in dendritic cells. Mol Cell Biol 34(5):888-899.
51. Souza CM, et al. (2012) The phosphatase PTP-PEST/PTPN12 regulates endothelial cell migration and adhesion, but not permeability, and controls vascular development and embryonic viability. J Biol Chem 287(51):43180-43190.
52. Rhee I, Davidson D, Souza CM, Vacher J, Veillette A (2013) Macrophage fusion is controlled by the cytoplasmic protein tyrosine phosphatase PTP-PEST/PTPN12. Mol Cell Biol 33(12):2458-2469.
53. Sahu SN, Nunez S, Bai G, Gupta A (2007) Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells. Am J Physiol Cell Physiol 292(6):C2288-C2296.
54. Villa-Moruzzi E (2013) PTPN12 controls PTEN and the AKT signalling to FAK and HER2 in migrating ovarian cancer cells. Mol Cell Biochem 375(1-2):151-157.
55. Li J, et al. (2015) Loss of PTPN12 stimulates progression of ErbB2-dependent breast cancer by enhancing cell survival, migration, and epithelial-to-mesenchymal transition. Mol Cell Biol 35(23):4069-4082.
56. Luo RZ, et al. (2014) Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma. PLoS One 9(1):e85592.
57. Sirois J, et al. (2006) Essential function of PTP-PEST during mouse embryonic vascularization, mesenchyme formation, neurogenesis and early liver development. Mech Dev 123(12):869-880.
58. Thieme S, et al. (2013) The histone demethylase UTX regulates stem cell migration and hematopoiesis. Blood 121(13):2462-2473.
59. Suvà ML, Riggi N, Bernstein BE (2013) Epigenetic reprogramming in cancer. Science 339(6127):1567-1570.
60. Kim JH, et al. (2014) UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res 74(6):1705-1717.
61. Zhang P, et al. (2014) ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol 16(9):864-875.
62. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA (2005) Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436(7048):221-226.
63. Quinlan AR, et al. (2010) Genome-wide mapping and assembly of structural variant breakpoints in the mouse genome. Genome Res 20(5):623-635.